Cerebral venous thrombosis (CVT) …

David S Liebeskind MD

Stroke & Vascular Disorders

Updated 04.21.2022
Released 04.10.1995
Expires For CME 04.21.2025

Cerebral venous thrombosis

Author: David S Liebeskind MD

See Contributor Disclosures

Editor: Steven R Levine MD

Cerebral venous thrombosis

In This Article

Quick Link

Introduction

Overview

Cerebral venous thrombosis is a rare but important cause of stroke that is often missed or delayed in diagnosis. The author of this article provides literature on the topic. The clinical manifestations are myriad, and a high level of suspicion must be maintained in order to effectively and expeditiously identify this disorder. Infectious and noninfectious processes may cause cerebral venous thrombosis. In the last several years, there has been increased presentation of cerebral venous thrombosis in patients with coronavirus disease 2019 (COVID-19), or after immunization against COVID-19 (02; 09). In adults, about half of cases are associated with pregnancy and the puerperium, but numerous unusual etiologies must be considered in the remainder of patients. Anticoagulation is the mainstay of therapy in the presence of either ischemic or hemorrhagic stroke; in some dire cases, more aggressive approaches such as thrombolysis or mechanical clot disruption may be undertaken.

Key points

	• Cerebral venous thrombosis is associated with an extensive range of medical disorders.
	• Treatment is primarily focused on thrombus resolution, with either anticoagulation or endovascular approaches in cases with rapid neurologic deterioration.
	• Intracerebral hemorrhage due to cerebral venous thrombosis is not necessarily a cause to withhold anticoagulation.

Historical note and terminology

Ribes made the first clinical description of cerebral venous thrombosis in 1825. In the preangiography era, the clinical presentation of progressive headache, papilledema, seizures, focal deficits, and coma led to the diagnosis of cerebral venous thrombosis, which was usually confirmed by the pathological findings of thrombosis of the major venous sinuses accompanied by hemorrhagic infarction. Cerebral angiography, CT, and MRI (28; 164) have facilitated the diagnosis of this entity and a wide range of clinical presentations has been depicted. Rigorous study of cerebral venous thrombosis has been limited due to its low incidence, and information has come mostly in the form of relatively small case series. However, in 2001, the International Study of Cerebral Vein Thrombosis completed prospective enrollment of 624 patients with this disorder and has provided a wealth of clinical data (62; 64). The overall incidence is estimated at 1.32 per 100,000 person-years (95% CI, 1.06-1.61), and among women between the ages of 31 and 50 years, the incidence is 2.78 (95% CI, 1.98-3.82) (46).

Clinical manifestations

Presentation and course

The clinical manifestations are dependent on the venous anatomy. However, involvement of multiple sinuses occurs in about half of cases.

Venous sinuses

Superior sagittal sinus. The superior sagittal sinus drains the major part of the cerebral cortices and plays a major role in the reabsorption of cerebrospinal fluid. It is involved in 70% of cases, and obstruction is manifested by increased intravenous and intracranial pressure. Patients usually present with headache, focal neurologic symptoms, seizures, and papilledema.

Lateral sinus. The lateral sinus, also called the transverse sinus, is involved in 60% to 70% of cases. It drains blood from the sagittal sinus, cerebellum (96), brainstem, and posterior part of the cerebral hemispheres. Isolated occlusion is rare; patients usually have thrombosis of multiple sinuses or cerebral veins. Patients usually present with headache, focal neurologic symptoms, seizures, and papilledema.

Cavernous sinus. The cavernous sinuses are located on each side of the sella turcica superolaterally to the sphenoid air sinuses. Cranial nerves III, IV, and V (V1 and V2 branches) course along the lateral wall of the cavernous sinuses; cranial nerve VI and the carotid artery run in the center. They drain blood from the orbits through the ophthalmic veins and from the anterior part of the base of the brain by the sphenoparietal sinus and middle cerebral veins. Because of their location, cavernous sinuses are often thrombosed in relation to infections of the face or sphenoid sinusitis. Cavernous sinus thrombosis comprises about 5% of all cerebral venous thrombosis cases. Patients usually present with headache, chemosis, proptosis, and painful ophthalmoplegia. Presentation can be more insidious, with only sixth nerve palsy, mild chemosis, and proptosis.

Cerebral veins

Superficial cerebral veins. Some of the cortical veins (frontal, parietal, and occipital) drain by ascending into the superior sagittal sinus, whereas the middle cerebral veins drain by descending toward the cavernous sinuses. Dilation and reversal of flow can occur when the sinus into which the veins drain is occluded due to thin walls and the absence of muscle fibers and valves in these veins. There is also anatomical variation in these veins, making it difficult to define a clinical syndrome of cortical vein thrombosis.

Deep cerebral veins. The deep cerebral veins, including the internal cerebral veins and the basal vein of Rosenthal, drain the deep white matter of the cerebral hemispheres and the basal ganglia. They are affected in 10% of cerebral venous thrombosis cases. Headache and changes in level of consciousness are seen with extensive involvement of this system (156). Severe presentations include focal findings, such as hemiparesis or aphasia, due to bilateral or unilateral edema and hemorrhagic infarction of the basal ganglia and thalami on brain imaging, particularly in young women (151; 37).

Veins of the posterior fossa. Venous drainage of the posterior fossa is divided into superior, anterior, and posterior veins that drain into the vein of Galen, petrosal sinus, and the torcular herophili, as well as the adjacent sagittal sinus and lateral sinus, respectively.

Prognosis and complications

In several series of cerebral sinus thrombosis, the reported mortality was between 6% and 30% (36; 50; 29). In the International Study of Cerebral Vein Thrombosis (ISCVT), mortality was only 4%, which was better than previously reported (64), and recent work suggests that mortality has been progressively declining over the last decade (48). Factors related to poor prognosis include involvement of deep cerebral sinuses, coma, hemiparesis, a large intracerebral hemorrhage or cerebral infarction, age of the patients (infants and the elderly), and the underlying cause (such as cancer or a concurrent neurologic disorder) (64; 73; 54). The presence of cortical venous involvement and parenchymal lesions has also been linked with worse outcomes (106). Overall, 39% of cases in the ISCVT had an intracranial hemorrhage at presentation. Older cases, men, those with thrombosis of the deep cerebral venous system or the right lateral sinus, and those with presence of a motor deficit were at higher risk for death or dependency at 6 months (72). A prognostic score has been developed based on the findings of the ISCVT (61; 94). For those patients who do survive, the outcome is usually good, with full recovery in about two thirds of patients (64). Persistent deficits in some patients can include optic nerve atrophy, hemiparesis, or epilepsy. Residual symptoms, albeit relatively minor, may affect the majority of individuals (83). Recurrence is relatively infrequent, yet repeated episodes may occur (15; 73). Age at cerebral venous thrombosis onset, nonadministration of anticoagulation, persistent venous occlusion, and presence of G20210A mutation in factor II predict recurrence in children (90). The risk of recurrent cerebral sinovenous thrombosis is low and is higher in the first year after discontinuation of anticoagulant treatment and among men (114).

Increasing attention has been devoted to the detection of patent foramen ovale as a cause for ischemic stroke due to paradoxical embolization from systemic veins. An extremely unusual case of paradoxical embolization following cerebral venous thrombosis has also been described (53).

Clinical vignette

A 22-year-old woman with a prior normal MR scan presented with sagittal and lateral sinus occlusion. Sagittal T1-weighted MR images 4 years earlier showed a normal sagittal sinus, whereas images taken later showed a clot within the sagittal sinus. Despite heparin therapy, the patient had a marked and progressive increase in intracranial pressure with loss of vision and was subsequently treated with multiple doses of intravenous tissue plasminogen activator. The patient's condition and thrombus formation stabilized, but the thrombus did not resolve despite thrombolytic therapy. Optic nerve fenestrations and finally a lumbar-peritoneal shunt successfully relieved the patient's symptoms of increased intracranial pressure.

Biological basis

Etiology and pathogenesis

Numerous predisposing factors for cerebral venous thrombosis have been reported and are present in the vast majority of cases; however, direct causal mechanisms are usually not identified.

Infectious causes. Bacterial sepsis or localized infection was formerly a common cause of cerebral venous thrombosis but has been remarkably reduced since the introduction of antibiotics. In a study published in 1985 by Bousser and colleagues, in a series of 38 patients, only 4 patients had cerebral venous thrombosis secondary to infection. In subsequent series of 135 patients collected by the same authors, only 9 cases were septic. Cavernous sinus thrombosis is the most common form of septic cerebral venous thrombosis, as a consequence of staphylococcus aureus infection of the middle third of the face. Other infection sources include sphenoid or ethmoid sinusitis, dental abscess, and otitis media. Cerebral venous thrombosis may also occur secondary to mastoiditis (91). Herpes zoster has also been associated with cerebral venous thrombosis (127; 167). Thrombosis has been described as a complication of coronavirus disease 2019 (COVID-19) (141; 146; 148; 166).

Hypercoagulability

Hormone-related hypercoagulability. The most common cause of cerebral venous thrombosis in women of childbearing age is hypercoagulability associated with the postpartum period, pregnancy, or oral contraceptive pills. In Bousser and colleagues’ series of 135 patients, the use of oral contraceptives was the only etiologic factor in 14 patients (10%). In the International Study on Cerebral Vein Thrombosis, oral contraceptives were used by 46% of the 464 women with this disorder (34). In a metaanalysis of the effect of oral contraceptive pills on stroke, current oral contraceptive pill users had a 16-fold increased risk of cerebral venous thrombosis compared to nonusers. Emergency contraception has also been associated with cerebral venous thrombosis (85). However, in developing countries, the puerperium is most frequently associated with this entity in young women. Cantu and Barinagarrementeria’s series of 113 hospitalized patients with cerebral venous thrombosis from Mexico City revealed that 57 cases (50%) occurred during the first 3 weeks postpartum.

Genetic prothrombotic disorders. Several genetic thrombophilias predispose to cerebral venous thrombosis (113). The hereditary resistance to activated protein C (also called APC-R) caused by the mutation in factor V (known as factor V Leiden) is the most common. The abnormally formed factor V is unable to be cleaved by activated protein C. This mutation is present in approximately 5% of Caucasians. A single gene defect confers increased risk, but this may not necessarily lead to thrombosis, unless an interaction with an environmental factor (eg, oral contraceptives or pregnancy) or another genetic risk factor is present. Deschiens and associates performed systematic coagulation studies in 40 patients with cerebral venous thrombosis and found that 4 cases (10%) had APC-R with heterozygous factor V Leiden; all of those cases were associated with other risk factors, including systemic lupus, antiphospholipid antibody syndrome, nephrotic syndrome (160), and cervical myelitis (55). TAFI gene polymorphisms have also been described in association with cerebral venous thrombosis (149).

Less common are deficiencies in protein C, protein S, and ATIII (approximately 1 person in 1000 to 5000 people). People with these congenital thrombophilias have a higher incidence of thrombosis than those with factor V Leiden. Cerebral venous thrombosis is the most common neurologic event in patients with these conditions (including factor V Leiden) and can occur in 1% to 3% of affected individuals. Deficiencies of protein C and protein S may also be acquired, particularly by protein wasting in the nephrotic syndrome.

Prothrombin gene variant (substitution of G to A in the prothrombin gene at nucleotide 20210 allele) has been associated with an increased risk for venous thrombosis, including cerebral venous thrombosis, in the setting of other risk factors (factor V Leiden or use of oral contraceptives). This condition is associated with elevated prothrombin levels and its prevalence in the Caucasian population is 2% (115; 100).

Voetsch and colleagues have also identified promoter polymorphisms in the plasma glutathione peroxidase (GPx-3) gene that may predispose to cerebral venous thrombosis (153). Factor XII C46T gene polymorphisms may also increase the risk of cerebral venous thrombosis (130).

Factor VIII elevations may also be associated with cerebral venous thrombosis (32; 89; 129).

Interestingly, the specific thrombophilias involved in cerebral venous thrombosis may differ with respect to disorders associated with deep venous thrombosis (159). A study protocol has been established by the Biorepository to Establish the Aetiology of Sinovenous Thrombosis (BEAST) that aims to recruit highly phenotyped cases to discern genetic links (42).

Acquired hypercoagulable disorders. Other coagulation disorders that are recognized as a cause or predisposing condition for cerebral venous thrombosis include disseminated intravascular coagulation, heparin-induced thrombocytopenia (65), plasminogen deficiency, epsilon aminocaproic acid treatment, sickle cell disease, polycythemia vera, paroxysmal nocturnal hemoglobinuria, thrombocythemia, antiphospholipid antibody syndrome (122), nephrotic syndrome, thyrotoxicosis (144; 23; 68), and hypercoagulability associated with malignancy. Anemia due to iron deficiency and other causes has also been associated with cerebral venous thrombosis (17; 143; 126; 78; 87; 125; 47; 25). Anemia has been confirmed as an overt risk factor for cerebral venous thrombosis (47). Elevated red cell distribution width has been associated with cerebral venous thrombosis (112).

Inflammatory disorders. Conditions such as lupus erythematosus, Behçet disease, sarcoidosis, ulcerative colitis, Crohn disease, and Wegener granulomatosis are associated with cerebral venous thrombosis (59; 157; 50; 07; 20; 41; 10). Cerebral venous thrombosis may be the first manifestation of an inflammatory systemic disease.

Structural damage to venous sinuses. Head trauma and intracranial surgeries are among the most common structural etiologies of cerebral venous thrombosis (57; 74; 11). Cutaneous infections or contusions can injure the diploic veins that connect to the scalp via emissary veins and drain in the superior sagittal sinus.

Miscellaneous causes. Arteriovenous malformations, tumors, carcinomatous meningitis, arachnoid cysts, local or surgical trauma to the jugular vein, high altitude exposure (40; 92), and electrical injury have also been associated with cerebral venous thrombosis (134). Intracranial hypotension and low CSF pressure syndromes have been associated with cerebral venous thrombosis, although the pathophysiologic links require further elucidation (97; 99; 131; 154; 124; 162). Thrombosis has also been noted as a complication of ventriculoperitoneal shunting (140; 12). Systemic venous thrombosis may also be associated.

Idiopathic causes. The proportion of cases of unknown etiology remains high, between 20% and 35% (34). In these cases, even after an extensive initial evaluation is performed, repeated investigations are advisable.

Multiple causes. Multiple predisposing factors were identified in 38% of the International Study of Cerebral Vein Thrombosis population.

The balance between procoagulant (clot-promoting) and anticoagulant (clot-preventing) mechanisms serves to prevent an excessive generation of thrombin when coagulation is triggered. This balance is determined by the levels of all coagulation factors (functional status) and fibrinolytic factors; its disturbance can result in thrombotic events, such as cerebral venous thrombosis. Damage in the endothelium of the vessel wall can also result in cerebral venous thrombosis. Other conditions such as dehydration, particularly in neonates, peripartum women, and elderly individuals can contribute to the development of cerebral venous thrombosis.

Venous occlusion can increase the venous pressure enough to lower the cerebral perfusion pressure, decreasing blood flow and, thus, leading to an area of infarction. Not every venous occlusion is followed by a venous infarction. Perfusion imaging techniques have demonstrated this effect of venous compromise on cerebral perfusion (51; 77).

Gross pathological examination usually reveals pallor and edema of the cortex in the area drained by the thrombosed vein. Multiple petechial hemorrhages can be observed. Thrombosed and dilated sinuses and cortical veins are seen on the brain surface, often accompanied by subarachnoid hemorrhage (22) or subdural hematoma (08; 18). Cerebral edema leads to flattened gyri. Microscopic changes reflect ischemic damage. There is loss of staining in the neuronal cytoplasm, nuclei are pyknotic, and the number is greatly reduced. Reactive gliosis can be seen (30).

Epidemiology

The incidence of cerebral venous thrombosis in the general population is unknown. However, several investigators have reported 3 to 5 new cases per year at a single busy general hospital (36; 29). The increased use of neuroimaging has likely led to higher incidence than previously estimated (56). The population subgroup with the highest risk appears to be women of childbearing age, particularly in the postpartum period. The incidence of cerebral venous thrombosis in the peripartum period in India is about 4.5 cases per 1000 obstetric admissions, compared to an incidence of less than 1 case in 3000 obstetric admissions in Western countries.

The International Study on Cerebral Vein and Sinus Dural Thrombosis collected prospective data regarding the clinical presentation, causes, risk factors, prognostic factors, currently applied treatments, complications, and outcomes of patients with cerebral sinus thrombosis. The study recruited 624 patients from 100 centers around the world.

Another high-risk group appears to be neonates or young infants in the setting of severe dehydration (21; 132; 31; 155; 121). In a community-based study of childhood stroke, Broderick and colleagues reported that 3 strokes of all 29 documented strokes were due to cerebral venous thrombosis (31). The cerebral vein thromboses occurred at 6 weeks (dehydration and postviral infection were the causes), 3 months (sagittal sinus thrombosis associated with acute lymphocytic leukemia was the cause), and 15 months (severe dehydration was the cause). Barron and colleagues reported 10 cases of cerebral venous thrombosis in neonates during a 10-year period (21). Thrombosis in these cases was usually associated with an acute systemic illness, such as shock or dehydration. Neonatal thrombosis may also reflect an underlying hematologic disorder (165). These data suggest that cerebral venous thrombosis is proportionally a more common cause of stroke in neonates and infants than in older children and adults. Mortality may be particularly high in this cohort (155).

Differential diagnosis

Isolated increased intracranial pressure is one of the most common clinical syndromes associated with cerebral venous thrombosis (29; 79). Benign intracranial hypertension or pseudotumor cerebri is frequently diagnosed in many of these patients, but this entity should be diagnosed only after excluding cerebral venous thrombosis by an appropriate imaging study. Severe elevations of intracranial pressure can mimic encephalitis or meningitis. Appropriate cerebrospinal fluid and radiological studies help to differentiate between these conditions.

Focal presentations such as stroke syndromes, seizures (focal or generalized), a combination of focal deficits, or a change in the level of consciousness are common. Determining whether the focal findings are due to a venous or arterial occlusion may be difficult. Infarct in an atypical arterial distribution with hemorrhage or surrounding “feathered” edema is characteristic of venous infarction.

Hemorrhagic infarction in patient with sagittal sinus thrombosis (CT)

A feathered pattern of edema surrounds the hemorrhage, which is atypical for arterial infarction and more typical of edema around a hemorrhagic tumor. (Used with permission. JP Broderick. Cerebral venous thrombosis. In: Feldman E,...

Other features that are typical of venous thrombosis are papilledema, bilateral edema, infarction, or hemorrhage in the upper part of the cerebral hemispheres or thalami. Cerebral venous thrombosis should be suspected in patients presenting with prominent and persistent seizure activity, prominent headache several days prior to the stroke, or symptoms in the setting of predisposing conditions such as puerperium or dehydration. Changes in headache characteristics, including exacerbation in head down position, may also herald cerebral venous thrombosis (147). Cerebral venous thrombosis typically manifests with holocranial and bifrontal headache of increasing severity (27). Use of an epidural blood patch for headache has also been implicated in cerebral venous thrombosis (95).

Diagnostic workup

Cerebral venous thrombosis has many potential clinical manifestations and, therefore, diagnosis may be challenging. Ultimately, neuroimaging is needed to detect this disorder. As an initial screening test for patients with suspected cerebral venous sinus thrombosis, D-dimer levels appear to be of value. Prior reports suggested that patients with D-dimer levels below 500 ng/mL are unlikely to have a cerebral venous sinus thrombosis (98), yet a negative D-dimer defined as lower than this threshold does not rule out the diagnosis (49). In the presence of isolated headache, such lower or negative values on D-dimer assays may provide a misleading diagnosis (49).

High-quality MRI is the initial procedure of choice for a patient suspected of suffering from cerebral venous thrombosis.

Superior sagittal sinus thrombosis (MRI) (1)

MRI of brain, axial FLAIR sequence, showing thrombosed superior sagittal sinus. (Contributed by Dr. Sudhir Kothari MD.)
Superior sagittal sinus thrombosis (MRI) (2)

T1-weighted sagittal MRI of brain, showing thrombosed superior sagittal sinus. (Contributed by Dr. Sudhir Kothari MD.)

MRI noninvasively detects absence of blood flow in cerebral venous sinuses, images the thrombus itself, demonstrates associated brain infarction, edema, or hemorrhage, detects structural causes of the thrombosed sinus (such as tumor), and rules out other conditions (such as arterial stroke or abscess).

Hemorrhagic cortical infarction (MRI)

This T2-weighted MRI shows hemorrhagic cortical infarction. (Contributed by Dr. Sudhir Kothari MD.)
Associated venous sinus occlusion (MR venogram)

(Contributed by Dr. Sudhir Kothari MD.)

Most importantly, it can be repeated to evaluate resolution or progression of thrombosis.

Selection of the correct MRI protocol is critical, and images in multiple planes and sequences must be evaluated by an experienced physician. For example, on some conventional T1- and T2-weighted MR images, flowing blood can be of high or low signal intensity, as well as isointense. In addition, the appearance of the thrombus itself changes over the first 3 weeks to 4 weeks (88). In the acute phase (day 1 to day 5), the thrombus usually appears strongly hypointense on T2-weighted images, and isointense on T1-weighted images. Magnetic resonance black-blood thrombus imaging may help localize the exact site of thrombosis and aid planning of endovascular treatment (164). Gradient echo imaging may be useful in detecting thrombus in this stage, when it is difficult to detect on other pulse sequences (103; 14). These signal changes correspond to the presence of deoxyhemoglobin and may mimic the appearance of a flow void in some cases. In the subacute stage (up to day 15), the thrombus signal is often strongly hyperintense on both T1-weighted and T2-weighted images as the release of extracellular methemoglobin develops.

Cerebral venous thrombosis (MRI)

Sagittal T1-weighted MR image of a 22-year-old woman from 1988 shows a normal sagittal sinus (A), whereas MR image from 1992 shows a clot within the sagittal sinus. Patient had marked and progressive increase in intracranial press...

In the third stage (after week 3), the thrombus signal is decreased in all sequences and shows increasing inhomogeneity. Finally, the fourth (late or chronic) stage is characterized by either the restitution of blood flow or the persistence of a residual thrombus.

Advances in flow-sensitive 2-dimensional time-of-flight MR, phase-contrast MR, or contrast-enhanced 3-dimensional time-of-flight MR angiography can provide an accurate picture of the presence or absence of flow within the major venous sinuses (88; 29; 117; 118).

Cerebral venous thrombosis (MRA)

Two-dimensional time-of-flight angiography in patient with cerebral venous thrombosis. (A) occluded sagittal sinus; (B) occluded lateral sinus; (C) patent straight sinus; (D) patent vein of Galen. (Used with permission. JP Broderi...

However, flow phenomena are not always straightforward and must be interpreted in light of the other standard MR sequences. In a prospective MRI study of cerebral venous thrombosis, Isensee and colleagues recommend the combined use of T1-weighted, spin-density, and single-slice, 2-dimensional, flow-sensitive sequences for the accurate diagnosis of an acute dural sinus thrombosis. However, accurate diagnosis and evaluation of third-stage and fourth-stage cerebral venous thrombosis may be difficult because of the evolution of the thrombus and partial recanalization of the venous sinus. MR venography is a readily available technique that may be more sensitive than MRI in diagnosing cerebral venous thrombosis. If the analysis of the magnetic resonance images is indeterminate and an older thrombosis is suspected clinically, conventional angiography should be performed (88). Artifacts on MRI may also occur, and conventional angiography should be considered when clinical suspicion remains (158).

MRI is not available in some institutions and is unobtainable in many patients who are intubated or uncooperative. Until the recent developments in MRI, CT of the brain was the initial test of choice in the diagnosis of cerebral venous thrombosis. Like MRI, it may rule out other conditions such as arterial strokes or tumors and visualizes cerebral edema, infarction, or hemorrhage associated with cerebral venous thrombosis (168).

Hemorrhagic infarction in patient with sagittal sinus thrombosis (CT)

With contrast administration, an "empty delta sign" may be seen, representing the opacification of collateral veins in the wall of the sagittal sinus surrounding the nonenhancing clot within the sinus (84; 29).

Sagittal sinus occlusion (CT)

Appearance of delta sign (black arrow) in patient with sagittal sinus occlusion. (Used with permission. JP Broderick. Cerebral venous thrombosis. In: Feldman E, editor. Current diagnosis in neurology. St. Louis: Mosby, 1994.)

However, the usefulness of this sign is limited because it is present in only 30% of reported cases. In addition, the posterior sagittal sinus divides into 2 channels in nearly a quarter of normal persons; the 2 channels can appear as a delta sign on CT imaging. Other CT findings include contrast enhancement of the falx and tentorium as well as small cerebral ventricles. The advent of multimodal CT, including noncontrast CT, CT angiography, and CT perfusion may provide a wealth of data for cerebral venous thrombosis, analogous to detailed MRI studies (77). CTA may reveal abnormalities even when symptoms are minimal in the presence of headache and when examination is normal (13). Although parenchymal definition of specific tissue changes may not be as detailed, CT venography can provide exquisite anatomic detail of thrombosed venous sinuses (107; 75). Cerebral venous collaterals are often noted; however, their presence does not seem to relate to clinical outcomes (19).

Cerebral angiography has been the gold standard in the diagnosis of cerebral venous thrombosis for many years. Four-vessel digital or conventional angiography, with visualization of the entire venous phase on at least 2 projections, is necessary. Partial or complete lack of filling of a sinus is the classic angiographic sign of cerebral venous thrombosis.

Sagittal sinus occlusion (angiogram)

Angiographic appearance of sagittal sinus occlusion (A). Note patent deep cerebral veins and sinuses. (Used with permission. JP Broderick. Cerebral venous thrombosis. In: Feldman E, editor. Current diagnosis in neurology. St. Loui...

However, the anterior part of the sagittal sinus may be absent in normal persons, and nearly one fifth of normal persons have partial or total agenesis of 1 lateral sinus. Nonfilling of the posterior portion of the sagittal sinus, the deep venous sinuses, or multiple sinus occlusions is the most specific radiographic marker of thrombosis. MRI is superior to cerebral angiography in that it not only visualizes the absence of blood flow but also the clot itself. Black-blood thrombus imaging has been demonstrated as a promising noninvasive diagnostic strategy (163). Angiography also carries some risk that the dehydrating effects of the contrast agent may result in progression of the thrombosis. In summary, multiple MR and MR angiographic sequences interpreted by an experienced neuroradiologist are the test of choice for suspected cerebral venous thrombosis. CT, followed by cerebral angiography, is another excellent diagnostic option. If MRI is inconclusive, cerebral angiography should be performed.

Cerebrospinal fluid examination is a useful diagnostic, and sometimes therapeutic, procedure. Evaluation of the cerebrospinal fluid can exclude infection or leptomeningeal cancer as a cause of the sinus thrombosis. Repeated lumbar drainage of cerebrospinal fluid may also relieve the symptoms of increased intracranial pressure (150). Some patients, however, may worsen with cerebrospinal fluid drainage in the setting of superior sagittal sinus thrombosis (128). It has been suggested that alleviating cerebrospinal fluid drainage may further decrease flow in these already thrombosed venous structures (128). Cerebrospinal fluid examination should be avoided, if possible, in the setting of an intracranial mass lesion such as a large cerebral infarction or hemorrhage. Cerebrospinal fluid findings in cerebral venous thrombosis include mild to moderate elevation of cerebrospinal fluid protein in two thirds of patients, greater than 20 red cells in two thirds of patients, and a mild pleocytosis in one third of patients (29). Increased cerebrospinal fluid pressure is seen in almost all patients with signs and symptoms of increased pressure.

EEG should be obtained in patients with cerebral venous thrombosis who are comatose or have had recurrent seizures. Seizures are common with cerebral venous sinus thrombosis (111), though it is not certain whether the occurrence of seizures impacts clinical outcome (63; 116). Nonconvulsive status epilepticus, periodic epileptiform discharges, or frequent electrographic seizures on an EEG may point to causes of unresponsiveness other than increased intracranial pressure or stroke that may respond to changes in anticonvulsant therapy. Other investigations include complete blood count, sedimentation rate, renal and liver panels, protime, partial thromboplastin time, antinuclear antibody, rheumatoid factor, serum protein electrophoresis, antiphospholipid antibodies, and chest x-ray. If an obvious cause of venous thrombosis is not found initially, a more extensive evaluation of the hemostatic and thrombolytic systems should be performed, such as protein C, protein S, antithrombin III, circulating lupus anticoagulant, and Leiden factor. If hemostatic abnormalities are detected, long-term anticoagulation will likely be needed.

Sinus thrombosis (CT)

Young male presents to the ER with a 4-day history of headaches and language difficulty. Axial unenhanced CT images of the head show high attenuation within the dural venous sinus compatible with sinus thrombosis. Clot is evident ...

Management

Treatment of cerebral venous thrombosis has 4 major components: (1) limitation or elimination of the thrombus, (2) treatment of the underlying cause of thrombus formation (if one is found), (3) treatment of seizures, and (4) management of increased intracranial pressure. However, treatment varies dramatically among centers (62). The efficacy of heparin in cerebral venous thrombosis has been demonstrated in a small randomized, placebo-controlled trial and in several large retrospective case series (58; 29; 104). Almost all patients with cerebral venous thrombosis should initially receive full-dose heparin (1.5 times to 2.0 times normal partial thromboplastin time). Studies suggest that even intracerebral hemorrhage is not necessarily a contraindication for anticoagulation in patients with severe and extensive cerebral venous thrombosis (58; 29).

Current recommendations include full-dose heparin (partial thromboplastin time 2.0 times to 2.5 times normal) in all patients without hemorrhage. A similar approach can be considered in patients with cerebral venous thrombosis and hemorrhagic infarction, but alternatively lower levels of anticoagulation with heparin (partial thromboplastin time 1.25 times to 1.5 times normal) can also be considered. Low molecular weight heparin and heparinoids could also be considered for use in patients with cerebral venous thrombosis. However, the single randomized trial of the low molecular weight heparin, nadroparin, showed only a trend (but not a definite pattern) toward more favorable outcomes than patients treated with placebo (52). In the International Study of Cerebral Vein Thrombosis, the vast majority (86%) of patients were treated with heparin or low molecular weight heparins, suggesting a consensus of opinion on its utility in this disease (62; 43). The introduction of novel anticoagulants, including factor Xa inhibitors, provides an alternative form of anticoagulation (71; 120; 123; 60; 38; 66). A systematic review of direct anticoagulants has also been undertaken (26; 136; 161).

Patients must be watched carefully for signs of clinical deterioration or marked increases in intracranial pressure. Duration of subsequent oral anticoagulation depends in part on the clinical picture and followup brain imaging (39). Warfarin (International Normalized Ratio 2.0 times to 3.0 times normal) is generally used for 6 months in stable patients without a defined cause and in whom the thrombus has remained stable or resolved at 6 months. Intervening clinical symptoms should be evaluated by followup MRI. If a persistent abnormality in the hemostatic or thrombolytic systems is discovered during laboratory testing, lifelong anticoagulation treatment may be considered.

Sources of systemic and local infection should be sought carefully for and treated with appropriate antibiotics. In particular, cavernous sinus thrombosis should be assumed to be due to infection until proven otherwise and should be treated with a combination of intravenous antibiotics and heparin. Intravenous steroids may be appropriate in patients with known lupus or Behçet disease (157; 20). Intravenous phenytoin or phenobarbital should be used to control seizures, but prophylactic antiepileptic treatment in a patient without seizures is not necessary.

One of the most difficult treatment issues is the control of increased intracranial pressure. Ideally, one should try initially to avoid dehydrating treatments such as mannitol and furosemide because they may lead to further clot extension. Acetazolamide may be associated with less dramatic fluid shifts and has been used by some investigators. Cerebrospinal fluid drainage by repeated lumbar punctures is a useful treatment option, but it is made more difficult by the frequent use of heparin. Steroids may be helpful if the elevation of pressure does not respond to drainage of cerebrospinal fluid, but this is controversial. Nevertheless, steroids are used in many centers and were administered to one quarter of the 624 patients in the International Study of Cerebral Vein Thrombosis (62). Steroids in the acute phase of cerebral venous thrombosis were not useful and were detrimental in patients without parenchymal cerebral lesions (35). If markedly elevated pressures persist and are accompanied by changes in the level of consciousness, an intracranial pressure monitor can guide therapy to decrease intracranial pressure. In extremely severe cases with progressive deterioration, pentobarbital-induced coma can effectively treat the pressure until the clot begins to lyse or collateral drainage develops (81). In patients with persistently increased intracranial pressure who have progressive visual loss due to optic nerve involvement, optic nerve fenestration can prevent loss of vision. Lumbar-peritoneal shunting should be reserved for patients with chronic symptomatic intracranial hypertension that is unresponsive to other therapies, as systematic review has questioned the overall benefit of shunting in this disorder (108). Decompressive hemicraniectomy may be considered in exceptional cases where mass effect is excessive (45; 101) as this procedure may be lifesaving, and authors suggest relatively good outcomes (01).

In some cases, the standard treatments may be unsuccessful, and the patient may develop worsening levels of consciousness or extension of the thrombus by brain imaging. In these settings, thrombolytic therapy may be considered. Smith and colleagues reported 7 patients who were successfully treated with heparinization and direct installation of a thrombolytic agent into the cerebral venous system via a catheter (139). All of these patients had clinical signs and symptoms of increased intracranial pressure (duration of symptoms 1 week to 6 months) that had not improved or had worsened with heparinization and standard medical therapy. None had evidence of hemorrhage on CT or MRI. Patients received urokinase doses ranging from 20,000 units per hour to 150,000 units per hour, with a mean infusion time to lysis of thrombus of 163 hours (range 88 hours to 244 hours). All patients with headache, papilledema, or focal neurologic findings improved. An infected access site and hematuria were the only complications. Horowitz and colleagues reported treatment of 13 patients with urokinase instilled in the intradural veins via a transfemoral catheter (86). Despite the presence of preinfusion infarcts in 5 patients, 4 of which were hemorrhagic, no major therapeutic morbidity occurred. Functional patency was achieved in 11 of 12 patients, and good to excellent clinical outcome was achieved in 10 of 11 patients with recanalization. The total dose of urokinase ranged from 1.5 million to 7 million units and the duration of treatment varied from 12 hours to 84 hours. The reason for the long infusion times is due to some organization of a large amount of longstanding thrombus. Others have reported effective thrombolytic treatment of superior sagittal sinus thrombosis and venous hemorrhagic infarction with an infusion of low-dose urokinase or tPA directly into the thrombus for up to several days via selective venous catheterization; all of them also received intravenous heparin for 36 hours to 84 hours (69). Angiographic patency was restored, and patients had dramatic clinical improvement. Shorter duration thrombolytic therapy may not result in recanalization. Several mechanical clot disruption techniques may be used as well, including use of the angiojet, stenting (67; 03), and other devices (04). Endovascular thrombectomy may now be performed with a variety of mechanical techniques and devices (145; 33), including direct aspiration (24; 80; 70; 105; 135; 93; 110; 164). Interestingly, the need for complete endovascular recanalization has been questioned (109). The design of a study comparing endovascular thrombolysis with anticoagulation has been detailed (44). A systematic review of 185 cases suggests reasonable safety, although a prospective randomized study is warranted (137; 138). The effect of systemic thrombolysis remains unknown due to lack of a controlled study (152). Spontaneous recanalization during anticoagulation may occur up to 1 year after onset (16; 82).

At present, thrombolytic therapy in patients with venous thrombosis should be considered experimental but worthy of consideration in dire circumstances (142). Unfortunately, the relatively small number of cases of cerebral venous thrombosis at a given institution and the lack of experience with thrombolytic infusion make a randomized trial comparing thrombolytic agents and heparin difficult. The TO-ACT trial, however, is now directly ascertaining this management question, comparing endovascular thrombectomy with anticoagulation (44). In practice, this option appears to be infrequently considered, as it was used in only 2% of the 624 patients in the International Study of Cerebral Vein Thrombosis (62).

Operative thrombectomy of the sagittal sinus, heparin, and pentobarbital coma have been used successfully in the treatment of a 16-year-old boy with extensive sagittal and lateral sinus thrombosis who was comatose with focal neurologic signs and had bilateral white matter ischemia or edema and markedly increased intracranial pressure.

In summary, almost all patients with cerebral venous thrombosis should receive intravenous heparin, treatment for the underlying cause (if known), and nondehydrating treatment for increased intracranial pressure. Patients with cerebral venous thrombosis who have parenchymal blood on brain imaging may still be candidates for heparin therapy, but only with close monitoring of the clinical state and brain images. Those patients who clinically worsen or who show clear evidence of clot extension on MR imaging, despite the best standard therapy including heparin, may be candidates for thrombolytic therapy. Use of thrombolytic therapy as an initial, first-line therapy requires further study.

Media

References

01: Aaron S, Alexander M, Moorthy RK, et al. Decompressive craniectomy in cerebral venous thrombosis: a single centre experience. J Neurol Neurosurg Psychiatry 2013;84(9):995-1000. PMID 23591554
02: Abdalkader M, Shaikh SP, Siegler JE, et al. Cerebral venous sinus thrombosis in COVID-19 patients: a multicenter study and review of literature. J Stroke Cerebrovasc Dis 2021;30(6):105733. PMID 33743411
03: Adachi H, Mineharu Y, Ishikawa T, et al. Stenting for acute cerebral venous sinus thrombosis in the superior sagittal sinus. Interv Neuroradiol 2015;21(6):719-23. PMID 26494402
04: Agner C, Deshaies EM, Bernardini GL, Popp AJ, Boulos AS. Coronary angiojet catheterization for the management of dural venous sinus thrombosis. Technical note. J Neurosurg 2005;103:368-71. PMID 16175870
05: Aguiar de Sousa D, Canhao P, Crassard I, et al. Safety of pregnancy after cerebral venous thrombosis: results of the ISCVT (International Study on Cerebral Vein and Dural Sinus Thrombosis)-2 pregnancy study. Stroke 2017;48(11):3130-3. PMID 28974635
06: Aguiar de Sousa D, Canhao P, Ferro JM. Safety of pregnancy after cerebral venous thrombosis: a systematic review. Stroke 2016;47(3):713-8. PMID 26797665
07: Aguiar de Sousa D, Mestre T, Ferro JM. Cerebral venous thrombosis in Behcet's disease: a systematic review. J Neurol 2011;258(5):719-27. PMID 21210139
08: Akins PT, Axelrod YK, Ji C, et al. Cerebral venous sinus thrombosis complicated by subdural hematomas: case series and literature review. Surg Neurol Int 2013;4:85. PMID 23869285
09: Al-Mufti F, Amuluru K, Sahni R, et al. Cerebral venous thrombosis in COVID-19: a New York Metropolitan Cohort Study. AJNR Am J Neuroradiol 2021;42(7):1196-200. PMID 33888450
10: Albakr AI, AlMohish N. Cerebral venous sinus thrombosis in inflammatory bowel disease: a review of published case reports. Perm J 2021;25:21.031. PMID 35348094
11: Alghamdi SR, Cho A, Lam J, Al-Saadi T. Cerebral venous sinus thrombosis in closed head injury: systematic review and meta-analysis. J Clin Neurosci 2022;98:254-260. PMID 35247707
12: Almeida LCA, Costa BS, de Lima FBF. Cerebral venous sinus thrombosis as a consequence of shunt hyperdrainage: a proposal of the pathophysiological mechanism and case report. Childs Nerv Syst 2022;38(1):25-32. PMID 34562131
13: Alons IME, Goudsmit BFJ, Jellema K, van Walderveen MAA, Wermer MJH, Algra A. Yield of computed tomography (CT) angiography in patients with acute headache, normal neurological examination, and normal non contrast CT: a meta-analysis. J Stroke Cerebrovasc Dis 2018;27(4):1077-84. PMID 29277281
14: Altinkaya N, Demir S, Alkan O, Tan M. Diagnostic value of T2*-weighted gradient-echo MRI for segmental evaluation in cerebral venous sinus thrombosis. Clin Imaging 2015;39(1):15-9. PMID 25148696
15: Amberger N, Weih M, Harms L, Valdueza JM. Third occurrence of cerebral venous thrombosis in a 33-year-old woman. Cerebrovasc Dis 2006;21:416-8. PMID 16549910
16: Arauz A, Vargas-Gonzalez JC, Arguelles-Morales N, et al. Time to recanalisation in patients with cerebral venous thrombosis under anticoagulation therapy. J Neurol Neurosurg Psychiatry 2016;87(3):247-51. PMID 25802120
17: Balci K, Utku U, Asil T, Buyukkoyuncu N. Deep cerebral vein thrombosis associated with iron deficiency anaemia in adults. J Clin Neurosci 2007;14(2):181-4. PMID 17161294
18: Bansal H, Chaudhary A, Mahajan A, Paul B. Acute subdural hematoma secondary to cerebral venous sinus thrombosis: case report and review of literature. Asian J Neurosurg 2016;11(2):177. PMID 27057237
19: Barboza MA, Mejias C, Colin-Luna J, Quiroz-Compean A, Arauz A. Intracranial venous collaterals in cerebral venous thrombosis: clinical and imaging impact. J Neurol Neurosurg Psychiatry 2015;86(12):1314-8. PMID 25589781
20: Barlas NY, Akman-Demir G, Bahar SZ. Cerebral venous thrombosis in the Mediterranean area in adults. Role of Behcet's disease as an underlying cause. Mediterr J Hematol Infect Dis 2011;3(1):e2011044. PMID 22110894
21: Barron TF, Gusnard DA, Zimmerman RA, Clancy RR. Cerebral venous thrombosis in neonates and children. Pediatr Neurol 1992;8(2):112-6. PMID 1580953
22: Benabu Y, Mark L, Daniel S, Glikstein R. Cerebral venous thrombosis presenting with subarachnoid hemorrhage: case report and review. Am J Emerg Med 2009;27:96-106. PMID 19041540
23: Bensalah M, Squizzato A, Ould Kablia S, Menia H, Kemali Z. Cerebral vein and sinus thrombosis and hyperthyrodism: a case report and a systematic review of the literature. Thromb Res 2011;128(1):98-100. PMID 21470669
24: Blackham KA. Extensive dural sinus thrombosis: successful recanalization with thrombolysis and a novel thrombectomy device. J Neurosurg 2011;114(1):133-5. PMID 20205511
25: Boon IS, Starkey KJ, Samsonova O, Johnston AM. In the thick of it: cerebral venous sinus thrombosis precipitated by iron-deficiency anaemia and sickle cell trait. BMJ Case Rep 2016;2016. PMID 27190121
26: Bose G, Graveline J, Yogendrakumar V, Fergusson D, Dowlatshahi D. Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review protocol. Syst Rev 2019;8(1):99. PMID 30999965
27: Botta R, Donirpathi S, Yadav R, Kulkarni GB, Kumar MV, Nagaraja D. Headache patterns in cerebral venous sinus thrombosis. J Neurosci Rural Pract 2017;8(Suppl 1):S72-7. PMID 28936075
28: Boukobza M, Crassard I, Bousser MG, Chabriat H. MR imaging features of isolated cortical vein thrombosis: diagnosis and follow-up. AJNR Am J Neuroradiol 2009;30:344-8. PMID 19095790
29: Bousser MG, Barnett HJ. Cerebral venous thrombosis. In: Barnett HJ, Mohr JP, Stein BM, Yatsu FM, editors. Stroke: pathophysiology, diagnosis, and management. 3rd ed. New York: Churchill Livingstone, 1998:623-47.
30: Bousser MG, Russell RR. Cerebral venous thrombosis. Paris: W.B. Saunders Company Ltd, 1997:16-8.
31: Broderick J, Talbot T, Prenger E, Leach A, Brott T. Stroke in children within a major metropolitan area: the surprising importance of intracerebral hemorrhage. J Child Neurol 1993;8:250-5. PMID 8409267
32: Bugnicourt JM, Roussel B, Tramier B, Lamy C, Godefroy O. Cerebral venous thrombosis and plasma concentrations of factor viii and von Willebrand factor: a case control study. J Neurol Neurosurg Psychiatry 2007;78(7):699-701. PMID 17189302
33: Bushnaq S, Kareem SA, Liaw N, et al. First off label endovascular clinical experience to treat diffuse cerebral venous sinus thrombosis using the INARI FlowTriever System: case report. Front Neurol 2021;12:778842. PMID 34975735
34: Canhao P, Bousser MG, Barinagarrementeria F, Stam J, Ferro JM; ISCVT collaborators. Predisposing conditions for cerebral vein and dural sinus thrombosis. J Neurology 2002;249(suppl 1):178.
35: Canhao P, Cortesao A, Cabral M, et al; ISCVT Investigators. Are steroids useful to treat cerebral venous thrombosis. Stroke 2008;39(1):105-10. PMID 18063833
36: Cantu C, Barinagarrementeria F. Cerebral venous thrombosis associated with pregnancy and puerperium. Stroke 1993;24:1880-4. PMID 8248971
37: Caplan LR, Wang Q. Thalamic lesions caused by deep cerebral venous thrombosis: a retrospective study. Eur Neurol 2015;74(1-2):118-26. PMID 26347040
38: Cappellari M, Bovi P. Direct oral anticoagulants in patients with cervical artery dissection and cerebral venous thrombosis. A case series and review of the literature. Int J Cardiol 2017;244:282-4. PMID 28629627
39: Caprio F, Bernstein RA. Duration of anticoagulation after cerebral venous sinus thrombosis. Neurocrit Care 2012;16(2):335-42. PMID 22189571
40: Cheng S, Chng SM, Singh R. Cerebral venous infarction during a high altitude expedition. Singapore Med J 2009;50:e306-8. PMID 19710966
41: Cognat E, Crassard I, Denier C, Vahedi K, Bousser MG. Cerebral venous thrombosis in inflammatory bowel diseases: eight cases and literature review. Int J Stroke 2011;6(6):487-92. PMID 22017824
42: Cotlarciuc I, Marjot T, Khan MS, et al. Towards the genetic basis of cerebral venous thrombosis-the BEAST Consortium: a study protocol. BMJ Open 2016;6(11):e012351. PMID 27881526
43: Coutinho JM, Ferro JM, Canhao P, et al. Unfractionated or low-molecular weight heparin for the treatment of cerebral venous thrombosis. Stroke 2010;41(11):2575-80. PMID 20930161
44: Coutinho JM, Ferro JM, Zuurbier SM, et al. Thrombolysis or anticoagulation for cerebral venous thrombosis: rationale and design of the TO-ACT trial. Int J Stroke 2013;8(2):135-40. PMID 22340437
45: Coutinho JM, Majoie CB, Coert BA, Stam J. Decompressive hemicraniectomy in cerebral sinus thrombosis: consecutive case series and review of the literature. Stroke 2009;40:2233-5. PMID 19372443
46: Coutinho JM, Zuurbier SM, Aramideh M, Stam J. The incidence of cerebral venous thrombosis: a cross-sectional study. Stroke 2012;43(12):3375-7. PMID 22996960
47: Coutinho JM, Zuurbier SM, Gaartman AE, et al. Association between anemia and cerebral venous thrombosis: case-control study. Stroke 2015;46(10):2735-40. PMID 26272383
48: Coutinho JM, Zuurbier SM, Stam J. Declining mortality in cerebral venous thrombosis: a systematic review. Stroke 2014;45(5):1338-41. PMID 24699058
49: Crassard I, Soria C, Tzourio C, et al. A negative D-dimer assay does not rule out cerebral venous thrombosis: a series of seventy-three patients. Stroke 2005;36:1716-9. PMID 16020765
50: Daif A, Awada A, Al-Rajeh S, et al. Cerebral venous thrombosis in adults. A study of 40 cases from Saudi Arabia. Stroke 1995;26(7):1193-5. PMID 7604412
51: Darwish RS, Amiridze NS. Brain perfusion abnormalities in patients with compromised venous outflow. J Neurol 2011;258(8):1445-50. PMID 21336780
52: de Bruijn SF, Stam J. For the Cerebral Venous Sinus Thrombosis Study Group. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke 1999;30:484-8. PMID 10066840
53: Del Sette M, Dinia L, Gandolfo C. Brain-to-brain paradoxical embolism through patent foramen ovale after cerebral vein thrombosis. Eur Neurol 2007;57(3):176-7. PMID 17218771
54: Dentali F, Poli D, Scoditti U, et al. Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. J Thromb Haemost 2012;10(7):1297-302. PMID 22578023
55: Deschiens MA, Conard J, Horellou MH, et al. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 1996;27(10):1724-30. PMID 8841318
56: Devasagayam S, Wyatt B, Leyden J, Kleinig T. Cerebral venous sinus thrombosis incidence is higher than previously thought: a retrospective population-based study. Stroke 2016;47(9):2180-2. PMID 27435401
57: Dobbs TD, Barber ZE, Squier WL, Green AL. Cerebral venous sinus thrombosis complicating traumatic head injury. J Clin Neurosci 2012;19(7):1058-9. PMID 22551588
58: Einhaupl K, Villringer A, Meister W, et al. Heparin treatment in sinus venous thrombosis. Lancet 1991;338(8767):597-600. PMID 1679154
59: Enevoldson TP, Russell RW. Cerebral venous thrombosis: new causes for an old syndrome. Q J Med 1990;77(284):1255-75. PMID 2149767
60: Feher G, Illes Z, Komoly S, Hargroves D. Novel oral anticoagulants in the treatment of cerebral venous thrombosis. Int Angiol 2016;35(4):365-8. PMID 25994451
61: Ferro JM, Bacelar-Nicolau H, Rodrigues T, et al. Risk score to predict the outcome of patients with cerebral vein and dural sinus thrombosis. Cerebrovasc Dis 2009;28:39-44. PMID 19420921
62: Ferro JM, Bousser MG, Barinagarrementeria F, Stam J, Canhao P; ISCVT collaborators. Variation in management of acute cerebral vein and dural sinus thrombosis. Cerebrovas Dis 2002a;13(suppl 3):60.
63: Ferro JM, Correia M, Rosas MJ, et al. Seizures in cerebral vein and dural sinus thrombosis. Cerebrovasc Dis 2003;15(1-2):78-83. PMID 12499715
64: Ferro JM, Stam J, Bousser MG, Barinagarrementeria F, Canhao P; ISCVT investigators. The prognosis of acute cerebral vein and dural sinus thrombosis. Cerebrovas Dis 2002b;13(suppl 3):100.
65: Fesler MJ, Creer MH, Richart JM, et al. Heparin-induced thrombocytopenia and cerebral venous sinus thrombosis: case report and literature review. Neurocrit Care 2011;15(1):161-5. PMID 20054716
66: Field TS, Camden MC, Al-Shimemeri S, Lui G, Lee AY. Off-label use of novel anticoagulants for treatment of cerebral venous thrombosis: A canadian survey. Int J Stroke 2017;12(9):NP16-18. PMID 26763915
67: Formaglio M, Catenoix H, Tahon F, Mauguiere F, Vighetto A, Turjman F. Stenting of a cerebral venous thrombosis. J Neuroradiol 2010;37(3):182-4. PMID 19782403
68: Franchini M, Lippi G, Targher G. Hyperthyroidism and venous thrombosis: a casual or causal association. A systematic literature review. Clin Appl Thromb Hemost 2011;17(4):387-92. PMID 20308227
69: Frey JL, Muro G, McDougall CG, Dean BL, Jahnke HK. Cerebral venous thrombosis. Combined intrathrombus rtPA and intravenous heparin. Stroke 1999;30:489-94. PMID 10066841
70: Gariel F, Berge J, Dousset V. Neurological recovery after coma related to diffuse cerebral venous sinus thrombosis. Interest in thrombi-aspiration with Penumbra system. Interv Neuroradiol 2015;21(2):218-21. PMID 25943847
71: Geisbusch C, Richter D, Herweh C, Ringleb PA, Nagel S. Novel factor xa inhibitor for the treatment of cerebral venous and sinus thrombosis: first experience in 7 patients. Stroke 2014;45(8):2469-71. PMID 25070963
72: Girot M, Ferro JM, Canhao P, et al. Predictors of outcome in patients with cerebral venous thrombosis and intracerebral hemorrhage. Stroke 2007;38(2):337-42. PMID 17204682
73: Gosk-Bierska I, Wysokinski W, Brown RD Jr, et al. Cerebral venous sinus thrombosis: Incidence of venous thrombosis recurrence and survival. Neurology 2006;67:814-9. PMID 16966543
74: Grangeon L, Gilard V, Ozkul-Wermester O, et al. Management and outcome of cerebral venous thrombosis after head trauma: a case series. Rev Neurol (Paris) 2017;173(6):411-7. PMID 28495232
75: Gratama van Andel HA, van Boven LJ, van Walderveen MA, et al. Interobserver variability in the detection of cerebral venous thrombosis using CT venography with matched mask bone elimination. Clin Neurol Neurosurg 2009;111:717-23. PMID 19560262
76: Grotta JC. Cerebral venous thrombosis: a new diagnosis in travel medicine. J Travel Med 1996;3(3):137. PMID 9815440
77: Gupta RK, Bapuraj JR, Khandelwal N, Khurana D. Prognostic indices for cerebral venous thrombosis on CT perfusion: a prospective study. Eur J Radiol 2014;83(1):185-90. PMID 24172883
78: Habis A, Hobson WL, Greenberg R. Cerebral sinovenous thrombosis in a toddler with iron deficiency anemia. Pediatr Emerg Care 2010;26(11):848-51. PMID 21057282
79: Haghighi AB, Edgell RC, Cruz-Flores S, et al. Mortality of cerebral venous-sinus thrombosis in a large national sample. Stroke 2012;43(1):262-4. PMID 21998058
80: Haghighi AB, Mahmoodi M, Edgell RC, et al. Mechanical thrombectomy for cerebral venous sinus thrombosis: a comprehensive literature review. Clin Appl Thromb Hemost 2013;20(5):507-15. PMID 23297370
81: Hanley D, Feldman E, Borel C, Rosenbaum A, Goldberg A. Treatment of sagittal sinus thrombosis associated with cerebral hemorrhage and intracranial hypertension. Stroke 1988;19:903-9. PMID 3388462
82: Herweh C, Griebe M, Geisbusch C, et al. Frequency and temporal profile of recanalization after cerebral vein and sinus thrombosis. Eur J Neurol 2016;23(4):681-7. PMID 26667584
83: Hiltunen S, Putaala J, Haapaniemi E, Tatlisumak T. Long-term outcome after cerebral venous thrombosis: analysis of functional and vocational outcome, residual symptoms, and adverse events in 161 patients. J Neurol 2016;263(3):477-84. PMID 26725090
84: Hoffmann MW, Bill PL, Bhigjee AI, Modi G, Haribhai HC, Kelbe C. The clinicoradiological profile of cerebral venous thrombosis. S Afr Med J 1992;82(5):341-8. PMID 1448716
85: Horga A, Santamarina E, Quilez A, de Francisco J, Garcia-Martinez R, Alvarez-Sabin J. Cerebral venous thrombosis associated with repeated use of emergency contraception. Eur J Neurol 2007;14(4):e5. PMID 17388977
86: Horowitz M, Purdy P, Unwin H, et al. Treatment of dural sinus thrombosis using selective catheterization and urokinase. Ann Neurol 1995;38(1):58-67. PMID 7611726
87: Huang PH, Su JJ, Lin PH. Iron deficiency anemia - a rare etiology of sinus thrombosis in adults. Acta Neurol Taiwan 2010;19(2):125-30. PMID 20714964
88: Isensee CH, Reul J, Thron A. Magnetic resonance imaging of thrombosed dural sinus. Stroke 1994;25:29-34. PMID 8266378
89: Kanazawa K, Takubo H, Nakamura Y, Ida M. Cerebral venous thrombosis with elevated factor VIII. Intern Med 2010;49(14):1461-2. PMID 20647670
90: Kenet G, Kirkham F, Niederstadt T, et al. Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: a multicentre cohort study. Lancet Neurol 2007;6(7):595-603. PMID 17560171
91: Kethireddy N, Sama S. Cerebral sinus venous thrombosis in the setting of acute mastoiditis. Cureus 2019;11(2):e4023. PMID 31007981
92: Khanal P, Thapa L, Shrestha AM, et al. Cerebral venous sinus thrombosis during Everest expedition: a case report and review of the literature. Case Rep Neurol Med 2016;2016:8314040. PMID 27872776
93: Kim H, Kim SR, Park IS, Kim YW. Treatment of the superior sagittal sinus thrombosis with the mechanical thrombectomy using stent-retriever device. J Korean Neurosurg Soc 2016;59:518-520. PMID 27651872
94: Koopman K, Uyttenboogaart M, Vroomen PC, van der Meer J, De Keyser J, Luijckx GJ. Development and validation of a predictive outcome score of cerebral venous thrombosis. J Neurol Sci 2009;276(1-2):66-8. PMID 18823637
95: Kueper M, Goericke SL, Kastrup O. Cerebral venous thrombosis after epidural blood patch: coincidence or causal relation. A case report and review of the literature. Cephalalgia 2008;28(7):769-73. PMID 18460011
96: Kulkarni GB, Mustare V, Abbas MM. Profile of patients with cerebral venous sinus thrombosis with cerebellar involvement. J Stroke Cerebrovasc Dis 2014;23(5):1106-11. PMID 24231137
97: Lai PH, Li JY, Lo YK, Wu MT, Liang HL, Chen CK. A case of spontaneous intracranial hypotension complicated by isolated cortical vein thrombosis and cerebral venous infarction. Cephalalgia 2007;27(1):87-90. PMID 17212690
98: Lalive PH, de Moerloose P, Lovblad K, et al. Is measurement of D-dimer useful in the diagnosis of cerebral venous thrombosis. Neurology 2003;61(8):1057-60. PMID 14581664
99: Lan MY, Chang YY, Liu JS. Delayed cerebral venous thrombosis in a patient with spontaneous intracranial hypotension. Cephalalgia 2007;27(10):1176-8. PMID 17784855
100: Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000;95:1517-32. PMID 10688804
101: Lanterna LA, Gritti P, Manara O, Grimod G, Bortolotti G, Biroli F. Decompressive surgery in malignant dural sinus thrombosis: Report of 3 cases and review of the literature. Neurosurg Focus 2009;26:E5. PMID 19485718
102: Laurichesse Delmas H, Winer N, Gallot D, et al. Prenatal diagnosis of thrombosis of the dural sinuses: report of six cases, review of the literature and suggested management. Ultrasound Obstet Gynecol 2008;32(2):188-98. PMID 18512853
103: Leach JL, Strub WM, Gaskill-Shipley MF. Cerebral venous thrombus signal intensity and susceptibility effects on gradient recalled-echo MR imaging. AJNR Am J Neuroradiol 2007;28(5):940-5. PMID 17494675
104: Levine SR, Twyman RE, Gilman S. The role of anticoagulation in cavernous sinus thrombosis. Neurology 1988;38:517-22. PMID 3281056
105: Liao W, Liu Y, Gu W, et al. Cerebral venous sinus thrombosis: successful treatment of two patients using the Penumbra System and review of endovascular approaches. Neuroradiol J 2015;28(2):177-83. PMID 25923675
106: Liang J, Chen H, Li Z, He S, Luo B, Tang S, Shang W, Zeng J. Cortical vein thrombosis in adult patients of cerebral venous sinus thrombosis correlates with poor outcome and brain lesions: A retrospective study. BMC Neurol 2017;17(1):219. PMID 29246198
107: Linn J, Ertl-Wagner B, Seelos KC, et al. Diagnostic value of multidetector-row CT angiography in the evaluation of thrombosis of the cerebral venous sinuses. AJNR Am J Neuroradiol 2007;28(5):946-52. PMID 17494676
108: Lobo S, Ferro JM, Barinagarrementeria F, Bousser MG, Canhao P, Stam J. Shunting in acute cerebral venous thrombosis: a systematic review. Cerebrovasc Dis 2013;37(1):38-42. PMID 24356100
109: Lozano-Ros A, Luque-Buzo E, Garcia-Pastor A, et al. Endovascular treatment of cerebral venous sinus thrombosis (CVST): is a complete recanalization required for a good clinical outcome? J Neuroradiol 2016;43(1):51-4. PMID 26517947
110: Ma J, Shui S, Han X, Guo D, Li TF, Yan L. Mechanical thrombectomy with Solitaire AB stents for the treatment of intracranial venous sinus thrombosis. Acta Radiol 2016;57(12):1524-30. PMID 26953230
111: Mahale R, Mehta A, John AA, et al. Acute seizures in cerebral venous sinus thrombosis: What predicts it? Epilepsy Res 2016;123:1-5. PMID 27023399
112: Maino A, Abbattista M, Bucciarelli P, et al. Red cell distribution width and the risk of cerebral vein thrombosis: a case-control study. Eur J Intern Med 2017;38:46-51. PMID 27823855
113: Marjot T, Yadav S, Hasan N, Bentley P, Sharma P. Genes associated with adult cerebral venous thrombosis. Stroke 2011;42(4):913-8. PMID 21350198
114: Martinelli I, Bucciarelli P, Passamonti SM, Battaglioli T, Previtali E, Mannucci PM. Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis. Circulation 2010;121(25):2740-6. PMID 20547928
115: Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral in thrombosis in carriers of a prothrombin gene mutation and in users of oral contraceptives. N Engl J Med 1998;338:1793-7. PMID 9632445
116: Masuhr F, Busch M, Amberger N, et al. Risk and predictors of early epileptic seizures in acute cerebral venous and sinus thrombosis. Eur J Neurol 2006;13:852-6. PMID 16879295
117: Meckel S, Glucker TM, Kretzschmar M, Scheffler K, Radu EW, Wetzel SG. Display of dural sinuses with time-resolved, contrast-enhanced three-dimensional MR venography. Cerebrovasc Dis 2008;25(3):217-24. PMID 18216463
118: Meckel S, Reisinger C, Bremerich J, et al. Cerebral venous thrombosis: diagnostic accuracy of combined, dynamic and static, contrast-enhanced 4d MR venography. AJNR Am J Neuroradiol 2010;31(3):527-35. PMID 19892813
119: Mehraein S, Ortwein H, Busch M, Weih M, Einhaupl K, Masuhr F. Risk of recurrence of cerebral venous and sinus thrombosis during subsequent pregnancy and puerperium. J Neurol Neurosurg Psychiatry 2003;74:814-6. PMID 12754362
120: Mendonca MD, Barbosa R, Cruz-e-Silva V, Calado S, Viana-Baptista M. Oral direct thrombin inhibitor as an alternative in the management of cerebral venous thrombosis: a series of 15 patients. Int J Stroke 2015;10(7):1115-8. PMID 25708372
121: Moharir MD, Shroff M, Pontigon AM, et al. A prospective outcome study of neonatal cerebral sinovenous thrombosis. J Child Neurol 2011;26(9):1137-44. PMID 21628696
122: Mokri B, Jack CR, Petty GW. Pseudotumor syndrome associated with cerebral venous sinus occlusion and antiphospholipid antibodies. Stroke 1993;24(3):469-72. PMID 8446985
123: Mutgi SA, Grose NA, Behrouz R. Rivaroxaban for the treatment of cerebral venous thrombosis. Int J Stroke 2015;10 Suppl A100:167-8. PMID 26502976
124: Nardone R, Caleri F, Golaszewski S, et al. Subdural hematoma in a patient with spontaneous intracranial hypotension and cerebral venous thrombosis. Neurol Sci 2010;31(5):669-72. PMID 20730465
125: Nicastro N, Schnider A, Leemann B. Iron-deficiency anemia as a rare cause of cerebral venous thrombosis and pulmonary embolism. Case Report Med 2012;2012:497814. PMID 22701123
126: Ogata T, Kamouchi M, Kitazono T, et al. Cerebral venous thrombosis associated with iron deficiency anemia. J Stroke Cerebrovasc Dis 2008;17(6):426-8. PMID 18984440
127: Panwar C, Singh S, Sharma N. Acute cerebral venous sinus thrombosis: a rare complication of primary varicella zoster virus infection. J Pediatr Neurosci 2020;15(2):116-9. PMID 33042243
128: Park JH, Yoon SH. New concept of cerebrospinal fluid dynamics in cerebral venous sinus thrombosis. Med Hypotheses 2008;70(1):143-7. PMID 17570605
129: Rawala MS, Noorani MM, Gulati R, Waqas S, Dave D. Elevated factor viii level associated with transverse cerebral venous sinus thrombosis. Am J Case Rep 2019;20:274-7. PMID 30824680
130: Reuner KH, Jenetzky E, Aleu A, et al. Factor XII C46T gene polymorphism and the risk of cerebral venous thrombosis. Neurology 2008;70(2):129-32. PMID 18180442
131: Richard S, Kremer S, Lacour JC, Vespignani H, Boyer P, Ducrocq X. Cerebral venous thrombosis caused by spontaneous intracranial hypotension: two cases. Eur J Neurol 2007;14(11):1296-8. PMID 17868278
132: Rivkin MJ, Anderson ML, Kaye EM. Neonatal idiopathic cerebral venous thrombosis: an unrecognized cause of transient seizures or lethargy. Ann Neurol 1992;32(1):51-6. PMID 1642472
133: Saadatnia M, Zare M, Fatehi F, Ahmadi A. The effect of fasting on cerebral venous and dural sinus thrombosis. Neurol Res 2009;31:794-8. PMID 19723447
134: Saito S, Tanaka SK. A case of cerebral sinus thrombosis developed during a high-altitude expedition to Gasherbrum I. Wilderness Environ Med 2003;14(4):226. PMID 14719856
135: Shaikh H, Pukenas BA, McIntosh A, Licht D, Hurst RW. Combined use of Solitaire FR and Penumbra devices for endovascular treatment of cerebral venous sinus thrombosis in a child. J Neurointerv Surg 2015;7(3):e10. PMID 24565759
136: Sheng S, Nalleballe K, Pothineni NV, et al. Use of direct oral anticoagulants in cerebral venous thrombosis: a systematic review. Blood Coagul Fibrinolysis 2020;31(8):501-5. PMID 32941197
137: Siddiqui FM, Dandapat S, Banerjee C, et al. Mechanical thrombectomy in cerebral venous thrombosis: systematic review of 185 cases. Stroke 2015;46(5):1263-8. PMID 25899238
138: Siddiqui FM, Weber MW, Dandapat S, et al. Endovascular thrombolysis or thrombectomy for cerebral venous thrombosis: study of nationwide inpatient sample 2004-2014. J Stroke Cerebrovasc Dis 2019;28(6):1440-7. PMID 30952531
139: Smith TP, Higashida RT, Barnwell SL, et al. Treatment of dural sinus thrombosis by urokinase infusion. AJNR Am J Neuroradiol 1994;15(5):801-7. PMID 8059645
140: Son WS, Park J. Cerebral venous thrombosis complicated by hemorrhagic infarction secondary to ventriculoperitoneal shunting. J Korean Neurosurg Soc 2010;48(4):357-9. PMID 21113365
141: Speeckaert MM, Speeckaert R, Delanghe JR. Potential underlying mechanisms of cerebral venous thrombosis associated with COVID-19. J Neuroradiol 2020;47(6):473-4. PMID 32620231
142: Stam J, Majoie CB, van Delden OM, van Lienden KP, Reekers JA. Endovascular thrombectomy and thrombolysis for severe cerebral sinus thrombosis: a prospective study. Stroke 2008;39(5):1487-90. PMID 18340091
143: Stolz E, Valdueza JM, Grebe M, et al. Anemia as a risk factor for cerebral venous thrombosis. An old hypothesis revisited. Results of a prospective study. J Neurol 2007;254(6):729-34. PMID 17450317
144: Strada L, Gandolfo C, Del Sette M. Cerebral sinus venous thrombosis in a subject with thyrotoxicosis and MTHFR gene polymorphism. Neurol Sci 2008;29(5):343-5. PMID 18941937
145: Styczen H, Tsogkas I, Liman J, Maus V, Psychogios MN. Endovascular mechanical thrombectomy for cerebral venous sinus thrombosis: a single center experience. World Neurosurg 2019;127:e1097-103. PMID 30980969
146: Sugiyama Y, Tsuchiya T, Tanaka R, et al. Cerebral venous thrombosis in COVID-19-associated coagulopathy: a case report. J Clin Neurosci 2020;79:30-2. PMID 33070913
147: Tan K, Venketasubramanian N, Hwang CY, Lim CC. My headache does not get better when I lie down: spontaneous intracranial hypotension complicated by venous thrombosis. Headache 2008;48(1):149-52. PMID 18184298
148: Thompson A, Morgan C, Smith P, et al. Cerebral venous sinus thrombosis associated with COVID-19. Pract Neurol 2020. [Epub ahead of print] PMID 33033161
149: Tokgoz S, Zamani AG, Durakbasi-Dursun HG, et al. TAFI gene polymorphisms in patients with cerebral venous thrombosis. Acta Neurol Belg 2013;113(3):291-7. PMID 23264082
150: Torikoshi S, Akiyama Y. Report of dramatic improvement after a lumboperitoneal shunt procedure in a case of anticoagulation therapy-resistant cerebral venous thrombosis. J Stroke Cerebrovasc Dis 2016;25(2):e15-9. PMID 26654661
151: van den Bergh WM, van der Schaaf I, van Gijn J. The spectrum of presentations of venous infarction caused by deep cerebral vein thrombosis. Neurology 2005;65:192-6. PMID 16043785
152: Viegas LD, Stolz E, Canhao P, Ferro JM. Systemic thrombolysis for cerebral venous and dural sinus thrombosis: a systematic review. Cerebrovasc Dis 2014;37(1):43-50. PMID 24356180
153: Voetsch B, Jin RC, Bierl C, et al. Role of promoter polymorphisms in the plasma glutathione peroxidase (GPx-3) gene as a risk factor for cerebral venous thrombosis. Stroke 2008;39(2):303-7. PMID 18096833
154: Wang YF, Fuh JL, Lirng JF, Chang FC, Wang SJ. Spontaneous intracranial hypotension with isolated cortical vein thrombosis and subarachnoid haemorrhage. Cephalalgia 2007;27(12):1413-7. PMID 17888012
155: Wasay M, Dai AI, Ansari M, Shaikh Z, Roach ES. Cerebral venous sinus thrombosis in children: a multicenter cohort from the United States. J Child Neurol 2008;23(1):26-31. PMID 18184940
156: Wasay M, Kojan S, Dai AI, Bobustuc G, Sheikh Z. Headache in cerebral venous thrombosis: incidence, pattern and location in 200 consecutive patients. J Headache Pain 2010;11(2):137-9. PMID 20112042
157: Wechsler B, Dellsola B, Vidailhet M, et al. MRI in 31 patients with Behcet's disease and neurological involvement: prospective study with clinical correlation. J Neurol Neurosurg Psychiatry 1993;56(7):793-8. PMID 8331356
158: White JB, Kaufmann TJ, Kallmes DF. Venous sinus thrombosis: a misdiagnosis using MR angiography. Neurocrit Care 2008;8(2):290-2. PMID 18080099
159: Wysokinska EM, Wysokinski WE, Brown RD, et al. Thrombophilia differences in cerebral venous sinus and lower extremity deep venous thrombosis. Neurology 2008;70(8):627-33. PMID 18285537
160: Xu H, Chen K, Lin D, Dai L, Chen H, Xu Z. Cerebral venous sinus thrombosis in adult nephrotic syndrome. Clin Nephrol 2010;74(2):144-9. PMID 20630135
161: Yaghi S, Shu L, Bakradze E, et al. Direct oral anticoagulants versus warfarin in the treatment of cerebral venous thrombosis (ACTION-CVT): A Multicenter International Study. Stroke 2022;53(3):728-38. PMID 35143325
162: Yamamoto Y, Yamamoto N, Fujita K, et al. Cerebral venous thrombosis: an unexpected complication with cerebrospinal fluid leaks after a fall in a patient with spinocerebellar ataxia type 6. Intern Med 2020;59(14):1749-53. PMID 32238726
163: Yang Q, Duan J, Fan Z, et al. Early detection and quantification of cerebral venous thrombosis by magnetic resonance black-blood thrombus imaging. Stroke 2016;47(2):404-9. PMID 26670082
164: Yang X, Wu F, Liu Y, et al. Predictors of successful endovascular treatment in severe cerebral venous sinus thrombosis. Ann Clin Transl Neurol 2019;6(4):755-61. PMID 31020000
165: Zanon E, Gentilomo C, Laverda A, et al. Cerebral sinus venous thrombosis with parenchymal infarcts in a newborn with severe haemophilia A and subdural haematomas. Haemophilia 2008;14(5):1117-21. PMID 18582228
166: Zhou Z, Kang H, Li S, Zhao X. Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms. J Neurol 2020;267(8):2179-84. PMID 32458193
167: Zhu R, Fang C, Wang J, He X. Acute herpes zoster followed by cerebral venous sinus thrombosis. Neurol India 2020;68(1):219-21. PMID 321292843
168: Zubkov AY, McBane RD, Brown RD, Rabinstein AA. Brain lesions in cerebral venous sinus thrombosis. Stroke 2009;40:1509-11. PMID 19182086

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

David S Liebeskind MD

Dr. Liebeskind of the University of California, Los Angeles, received consulting fees for core lab activities from Cerenovus, Genentech, Medtronic, Rapid Medical, and Stryker.
See Profile

Editor

Steven R Levine MD

Dr. Levine of the SUNY Health Science Center at Brooklyn has no relevant financial relationships to disclose.
See Profile

Former Authors

Joseph P Broderick MD (original author), Scott E Kasner MD, and Ximena Morales MD

Patient Profile

Age range of presentation: 0 month to 65+ years
Sex preponderance: female>male, >1:1
Heredity: none
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Cerebral venous thrombosis

Associated Disorders

coagulation disorders
Hypercoagulable states and cerebrovascular disease
Inflammatory disorders
Neurovascular injuries
many associated conditions

Differential Diagnosis

cerebral arterial infarction
Nontraumatic intracerebral hemorrhage
encephalitis
Idiopathic intracranial hypertension
meningitis
- stroke syndromes

Also Relevant

Acute headache: diagnosis
Antiphospholipid antibody syndrome
Carotid-cavernous fistulas
Cerebral venous thrombosis in infants and children
Combined third, fourth, and sixth nerve palsies
- Headache associated with hormonal fluctuations
- Hormonal contraception and stroke
- Hypercoagulable states and cerebrovascular disease
- Hyperhomocysteinemia
- Idiopathic intracranial hypertension
- Pregnancy and epilepsy
- Pregnancy and stroke
- Pregnancy: CNS complications
- Seizures associated with eclampsia
- Sex hormones and the nervous system
- Stroke in young adults

Clinical Categories

Patient Handouts

Behcet disease

Web References

Guidelines

NORD: Paroxysmal nocturnal hemoglobinuria

Cerebral venous thrombosis (CVT) …

Cerebral venous thrombosis

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Brain death/death by neurologic criteria

Acute cerebellar ataxia in children

Hepatic encephalopathy

Bowel dysfunction in neurologic disorders

Zika virus: neurologic complications

Coma due to primary brainstem and diencephalic lesions

Cerebral edema in childhood

Transient visual loss

Cerebral venous thrombosis

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Brain death/death by neurologic criteria

Acute cerebellar ataxia in children

Hepatic encephalopathy

Bowel dysfunction in neurologic disorders

Zika virus: neurologic complications

Coma due to primary brainstem and diencephalic lesions

Cerebral edema in childhood

Transient visual loss

This is an article preview.
Start a Free Account
to access the full version.